Wall Street analysts will be watching closely when TherapeuticsMD, Inc. (NASDAQ:TXMD) reports its quarterly earnings next, which is scheduled for Tue 19 Feb (In 44 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at -$0.17 per share. In the preceding quarter, the company reportedly generated EPS of -$0.16 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of , a profit margin of and a gross margin of 84.30%.
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of TherapeuticsMD, Inc. (NASDAQ:TXMD). Most recently, on June 15th, 2018, JP Morgan Initiated a Overweight rating. Before that, on September 8th, 2017, Morgan Stanley Initiated to Equal-Weight. Oppenheimer Upgrade a Outperform rating on July 11th, 2017, Oppenheimer Downgrade an Perform rating on May 9th, 2017, and Jefferies Resumed a Buy rating on November 22nd, 2016.
At its current price point, combined with the fact that this company has 221.34M shares outstanding, the current market capitalization sits at 922.99M. In the last trading day, 3,252,892 shares of TherapeuticsMD, Inc. were traded, which compares to its usual volume of about 3.32M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $0.21 in the past five trading days, resulting in a percentage change of +6.38% and a moving average of 3.93. In the past 20 days, its price changed by -$0.68 (which is -14.02%) and the stock’s moving average was 3.96. Looking back a full 50 days, shares of TXMD changed by -$1.20 (which is -22.35%) and demonstrated a moving average of 4.55.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 81.55%, a 14-day Stochastic %K score of 62.72% and a 20-day Stochastic %K score of 30.92%. Using a similar metric, TherapeuticsMD, Inc. (TXMD) shares showed a Stochastic %D of 72.99% over the past 9 days, a Stochastic %D score of 46.15% over the last 14 days, and a 20-day Stochastic %D of 23.03%. Meanwhile, this stock’s MACD Oscillator was 0.11 over the past 9 days, 0.17 over the past two weeks, and 0.01 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $4.17 level. Over the past 12 months, this stock has experienced a high price of $7.66 and a low of $3.51. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
T Rowe Price Associates Inc purchased more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from TherapeuticsMD, Inc. (NASDAQ:TXMD) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 25,319,433 shares of the company’s stock following the addition of 1,915,124 to this investor’s holdings during the three-month period. This share count represents that T Rowe Price Associates Inc now held 10.64% stake in TherapeuticsMD, Inc. (TXMD)’s shares.
Just in the most recent trading day, TherapeuticsMD, Inc. (NASDAQ:TXMD) experienced a high price of $4.2 and low point of $3.87. At the end of the last trading session, this stock was at 4.17 per share, following a gain of $0.06, or 8.03% during the full day.